Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Oppenheimer Asset Management raised its Genmab stake by 15.5%, buying 48,894 shares to hold 364,756 shares (about 0.06% of the company) valued at $11.23 million per its latest 13F filing.
• Several brokers have recently upgraded GMAB—Jefferies initiated coverage at "buy" ($41.50 TP) and others moved to "buy"/"strong-buy"—leaving a consensus rating of "Moderate Buy" with an average price target of $39.07 versus the current stock price around $26.45.
• In its latest quarter Genmab missed EPS ($0.05 vs. $0.46 expected) while revenue matched expectations at $1.06 billion; the stock trades at a PE of 17.06 and a 12‑month range of $18.89–$35.43.

Oppenheimer Asset Management Inc. raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 364,756 shares of the company's stock after purchasing an additional 48,894 shares during the quarter. Oppenheimer Asset Management Inc. owned 0.06% of Genmab A/S worth $11,234,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of GMAB. EverSource Wealth Advisors LLC lifted its position in Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock valued at $44,000 after purchasing an additional 1,174 shares during the last quarter. Sei Investments Co. raised its stake in shares of Genmab A/S by 4.2% in the second quarter. Sei Investments Co. now owns 62,111 shares of the company's stock valued at $1,283,000 after acquiring an additional 2,496 shares during the period. Squarepoint Ops LLC raised its stake in shares of Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company's stock valued at $1,947,000 after acquiring an additional 81,434 shares during the period. Quantinno Capital Management LP raised its stake in shares of Genmab A/S by 64.9% in the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company's stock valued at $3,267,000 after acquiring an additional 62,226 shares during the period. Finally, Raymond James Financial Inc. raised its stake in shares of Genmab A/S by 48.1% in the second quarter. Raymond James Financial Inc. now owns 31,146 shares of the company's stock valued at $643,000 after acquiring an additional 10,113 shares during the period. Institutional investors own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GMAB. Jefferies Financial Group began coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a "buy" rating and a $41.50 target price on the stock. BNP Paribas Exane raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, April 22nd. The Goldman Sachs Group raised shares of Genmab A/S from a "neutral" rating to a "buy" rating in a research note on Wednesday, April 22nd. Truist Financial raised shares of Genmab A/S to a "strong-buy" rating in a research note on Monday, April 27th. Finally, Guggenheim reduced their target price on shares of Genmab A/S from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus price target of $39.07.

Genmab A/S Trading Down 0.3%

GMAB stock opened at $26.45 on Friday. The company has a market capitalization of $16.99 billion, a PE ratio of 17.06, a P/E/G ratio of 1.19 and a beta of 0.86. Genmab A/S Sponsored ADR has a 12 month low of $18.89 and a 12 month high of $35.43. The firm's 50-day moving average is $27.43 and its 200 day moving average is $30.06. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. On average, research analysts anticipate that Genmab A/S Sponsored ADR will post 1.18 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.